A5062344658- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Eosinophilic Disorders and Syndromes
- Galectins and Cancer Biology
- CAR-T cell therapy research
- Immunodeficiency and Autoimmune Disorders
- Viral-associated cancers and disorders
- Kruppel-like factors research
- Peroxisome Proliferator-Activated Receptors
- Cancer Genomics and Diagnostics
- RNA Research and Splicing
- Cytokine Signaling Pathways and Interactions
- Immune Cell Function and Interaction
- PI3K/AKT/mTOR signaling in cancer
- Acute Lymphoblastic Leukemia research
- RNA modifications and cancer
- Radiopharmaceutical Chemistry and Applications
- Advancements in Semiconductor Devices and Circuit Design
- Biochemical and Molecular Research
- Mycobacterium research and diagnosis
- RNA and protein synthesis mechanisms
China Institute of Atomic Energy
2025
Fox Chase Cancer Center
2020-2025
Army Medical University
2023-2025
Fujian Medical University
2025
Chongqing Medical University
2025
Second Affiliated Hospital of Chongqing Medical University
2025
Dalian Medical University
2025
Pfizer (United States)
2021-2025
Xuzhou Medical College
2024
Nanjing University of Chinese Medicine
2024
Ibrutinib has generated remarkable responses in patients with chronic lymphocytic leukemia (CLL), including those an unfavorable cytogenetic profile. However, develop resistance, poor outcomes and no established treatment options. Mutations BTK PLCG2 have emerged as main mechanisms of drug but not all carry these mutations. Further understanding resistance is urgently needed will support rational development new therapeutic strategies. To that end, we characterized the genomic profiles...
Background This study evaluates the correlation between imatinib trough plasma concentrations (Cmin) and clinical response safety in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia phase Tyrosine Kinase Inhibitor OPtimization Selectivity (TOPS) trial.Design Methods Patients were randomized 1:2 to 400 mg/day or 800 imatinib. Imatinib Cmin levels collected at pre-dose before treatment, end of months 1 (day 29), 6, 9, 12.Results stable over time dose arm,...
Melanoma is the fifth most common cancer in United States. The advent of immunotherapy and molecular targeted therapy has improved progression-free overall survival many patients with advanced disease. However, selection therapeutic choices requires a nuanced approach, especially when considering molecularly agents. This case report highlights diagnostic challenge managing patient history chronic lymphocytic leukemia (CLL) recurrent melanoma. Molecular testing suggested discordant BRAF V600E...
// Shruti Sharma 1, * , Natalie Galanina 2, Ailin Guo Jimmy Lee 1 Sabah Kadri 3 Charles Van Slambrouck Bradley Long Weige Wang Mei Ming Larissa V. Furtado Jeremy P. Segal Wendy Stock 2 Girish Venkataraman Wei-Jen Tang 4 Pin Lu Yue Lynn Department of Pathology, University Chicago, IL 60637, USA Medicine, Center for Research Informatics, Ben-May Cancer Research, These authors have contributed equally to this work Correspondence to: Wang, email: ylwang@bsd.uchicago.edu Keywords: chronic...
Summary Ibrutinib inhibits B ruton tyrosine kinase ( BTK ), a key component of early B‐cell receptor BCR ) signalling pathways. A multicentre phase 2 trial ibrutinib in patients with relapsed/refractory mantle cell lymphoma MCL demonstrated remarkable response rate. However, approximately one‐third have primary resistance to the drug while other appear lose and develop secondary resistance. Understanding molecular mechanisms underlying sensitivity is paramount importance. In this study, we...
RIG-I is a key cytosolic pattern recognition receptor that interacts with MAVS to induce type I interferons (IFNs) against RNA virus infection. In this study, we found cyclophilin A (CypA), peptidyl-prolyl cis/trans isomerase, functioned as critical positive regulator of RIG-I-mediated antiviral immune responses. Deficiency CypA impaired IFN production and promoted viral replication in human cells mice. Upon Sendai infection, increased the interaction between its E3 ubiquitin ligase TRIM25,...
To explore the autoimmune response and outcome in central nervous system (CNS) at onset of viral infection correlation between autoantibodies viruses. Methods A retrospective observational study was conducted 121 patients (2016–2021) with a CNS confirmed via cerebrospinal fluid (CSF) next-generation sequencing (cohort A). Their clinical information analysed CSF samples were screened for against monkey cerebellum by tissue-based assay. In situ hybridisation used to detect Epstein-Barr virus...
Thiazolidinediones (TZDs) are widely used for treatment of type 2 diabetes mellitus. Peroxisome proliferator-activated receptor gamma (PPAR gamma) is the molecular target TZDs and believed to mediate apoptotic effects this class drugs in a variety cell types, including B T lymphocytes. The finding that induce lymphocyte death has raised concerns regarding whether might further impair immune functions diabetics. To address issue, we investigated roles PPAR survival. was up-regulated upon...
We investigated intracellular localization and substrate specificity of P21-activated kinase-1 (Pak1) in rat cardiac myocytes. Pak1 is a serine/threonine protein kinase that activated by Rac1/Cdc42 important signaling stress responses. Yet the vivo function heart cells poorly understood. Studies reported here indicate physically interacts with phosphatase 2a localizes to Z-disk, cell membrane, intercalated disc, nuclear membrane adult compared levels phosphorylation troponin I (cTnI) control...
Abstract Purpose: Patients with B-cell lymphomas often relapse after frontline therapy, and novel therapies are urgently needed to provide long-term remission. We established lymphoma patient-derived xenograft (PDX) models assess their ability mimic tumor biology identify patient treatment options. Experimental Design: the PDX from 16 patients diffuse large lymphoma, mantle cell follicular marginal zone or Burkitt by inoculating cells into a human bone chip implanted mice. subjected...